Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 26 Show results per page	View Search Criteria \| Help With Results

Last Modified: 7/20/2007 First Published: 3/1/2002


1.		Phase I/II Study of Yttrium Y 90-Labeled Ibritumomab Tiuxetan With Rituximab in Patients With B-Cell Non-Hodgkin's Lymphoma Who Have Relapsed After High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Completed				19 and over				Other				UNMC-535-00 NCI-V02-1691, NCT00031642

Last Modified: 10/12/2004 First Published: 6/23/2003


2.		Phase I/II Study of Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Patients With Post-Transplant Lymphoproliferative Disorder

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Completed				18 and over				NCI				AMC-037 NCT00064246

Last Modified: 1/21/2008 First Published: 7/23/2004


3.		Phase I/II Study of Motexafin Gadolinium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Patients With Bulky Stage II or Stage III or IV Relapsed or Refractory CD20-Positive Non-Hodgkin's Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				18 and over				NCI, Pharmaceutical / Industry				NU-02H8 NU-0228-024, PCI-P-PCYC-0213, NCT00089284

Last Modified: 3/3/2008 First Published: 8/24/2006


4.		Phase I/II Study of Bortezomib, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Patients With Relapsed or Refractory Follicular Non-Hodgkin's Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Completed				18 and over				NCI, Pharmaceutical / Industry				NU-05H9 NU-0522-060, MILLENNIUM-NU-05H9, NCT00372905


5.		Radioimmunotherapy With 90Y-Ibritumomab Tiuxetan as Part of a Dose Reduced Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation for the Treatment of Non-Hodgkin Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Completed				18 to 70				Other				2005-002206-37 NCT00302757

Last Modified: 3/10/2008 First Published: 11/21/2007


6.		Phase I/II Study of Yttrium Y 90 Ibritumomab Tiuxetan in Combination With High-Dose Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplantation in Patients With Poor-Risk, Relapsed, or Refractory B-Cell Non-Hodgkin Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				18 to 60				NCI				CHNMC-98153 98153, NCT00562978

Last Modified: 10/23/2008 First Published: 3/24/2003


7.		Phase II Study of Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Combined With Yttrium Y 90 Ibritumomab Tiuxetan in Patients Age 60 and Over With Previously Untreated Diffuse Large B-Cell Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Supportive care, Treatment				Closed				60 and over				NCI				MSKCC-02090 NCT00058422

Last Modified: 7/23/2007 First Published: 5/23/2003


8.		Phase II Study of Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Patients With Transformed CD20+ B-Cell Non-Hodgkin's Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				NCI				CALGB-50201 NCT00062114, SWOG-C50201, ECOG-C50201

Last Modified: 12/12/2007 First Published: 9/24/2003


9.		Phase II Study of Rituximab and CHOP Chemotherapy Comprising Prednisone, Cyclophosphamide, Doxorubicin, and Vincristine Followed By Yttrium Y 90 Ibritumomab Tiuxetan (Yttrium Y 90 Zevalin®) in Patients With Previously Untreated Mantle Cell Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI				ECOG-E1499 E1499, NCT00070447


10.		Study Of Yttrium-Ibritumomab (Zevalin) For the Treatment Of Patients With Relapsed And Refractory Mantle Cell Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				Other				ID01-541 NCT00038623

Select All on One Page


					1 2 3 Next >

| | | | | | | |

A Service of the National Cancer Institute